Последние темы
Похожие темы
Праздники Исландии
Вход
Actavis opens labs in Florida
Страница 1 из 1
Actavis opens labs in Florida
New analytical and research and development laboratories were opened in a United States division of the international generic pharmaceutical company Actavis.
The labs help expand the research and development efforts for controlled release drugs and other technically difficult generic pharmaceutical products.
The premises have been expanded by about 300 sq metres and the new R&D labs have been expanded by about 140 sq metres.
Recently launched Actavis South Atlantic products in the United States include Bupropion, the generic equivalents of GlaxoSmithKline’s Wellbutrin as well as Nifedipine, the generic equivalent of Bayer’s Adalat.
“Actavis in the United States is focused on our vision and commitment to be on the cutting edge of new technology. The expansion of our South Atlantic R&D facility ensures that we remain well-positioned to develop and manufacture XL (extended release) and CR (continuous release) drugs,” said Doug Boothe, Actavis U.S. CEO.
Actavis is one of the leading companies in the U.S. market in the development of continuous release products, with more than EUR 50 million expected to be invested in their development in 2008.
The Florida investments are the latest in a spate of recent expansion news from Iceland-based Actavis reported on IceNews and elsewhere. The company also announced its formal launch onto the French generic pharmaceuticals market last week.
icenews.is
The labs help expand the research and development efforts for controlled release drugs and other technically difficult generic pharmaceutical products.
The premises have been expanded by about 300 sq metres and the new R&D labs have been expanded by about 140 sq metres.
Recently launched Actavis South Atlantic products in the United States include Bupropion, the generic equivalents of GlaxoSmithKline’s Wellbutrin as well as Nifedipine, the generic equivalent of Bayer’s Adalat.
“Actavis in the United States is focused on our vision and commitment to be on the cutting edge of new technology. The expansion of our South Atlantic R&D facility ensures that we remain well-positioned to develop and manufacture XL (extended release) and CR (continuous release) drugs,” said Doug Boothe, Actavis U.S. CEO.
Actavis is one of the leading companies in the U.S. market in the development of continuous release products, with more than EUR 50 million expected to be invested in their development in 2008.
The Florida investments are the latest in a spate of recent expansion news from Iceland-based Actavis reported on IceNews and elsewhere. The company also announced its formal launch onto the French generic pharmaceuticals market last week.
icenews.is
Страница 1 из 1
Права доступа к этому форуму:
Вы не можете отвечать на сообщения
|
|
Пн Апр 29, 2024 7:07 am автор Джетт
» Тиманский овраг
Ср Дек 27, 2023 10:47 pm автор Джетт
» Отель "Ореанда"
Вс Сен 10, 2023 8:05 am автор Джетт
» Карельские рассветы
Вс Апр 23, 2023 7:36 am автор Джетт
» Альма-Матер
Вс Дек 25, 2022 6:42 am автор Джетт
» Две вдовы Маленького Принца
Вс Авг 28, 2022 6:47 am автор Джетт
» Самый сочный шашлык - рецепты, маринады и другие хитрости
Вс Июн 12, 2022 11:34 pm автор drogbank
» Сентябрь в Алустосе
Чт Май 26, 2022 5:16 am автор Джетт
» Кронштадтский тупик
Вс Дек 05, 2021 7:22 am автор Джетт
» Говяжий язык
Ср Ноя 17, 2021 11:06 am автор drogbank